LUXEMBOURG--(BUSINESS WIRE)--Advanced
Biological Laboratories (ABL), S.A, and Mayo Medical Laboratories
have announced a collaboration agreement to develop a deep-sequencing
pipeline for novel diagnostic laboratory-developed tests. The novel
tests will be validated using clinical samples selected by the Mayo
Clinic Division of Clinical Microbiology. The collaboration will also
seek to generate a sequence database to which clinical isolates can be
compared. Advanced information technology developments will be led by
ABL under the expertise of Mayo Clinic staff.
Based in Luxembourg,
Advanced Biological Laboratories develops information technology and
health solutions for patient management and sequencing data analysis.
Mayo Medical Laboratories is the reference laboratory of Mayo Clinic,
the world-renowned health care organization located in Rochester,
Minnesota.
“Properly validated and characterized
laboratory-developed tests offer valuable direction to clinicians and
virologists. They guide the selection of optimal treatments and
diagnostic monitoring for patients suffering from genetically variable
virological diseases of either an acute or chronic nature,” says ABL
Chief Executive Officer Chalom Sayada, M.D., Ph.D. “When developed in a
timely manner, these tests can be crucial to improved clinical outcomes
and decreases in treatment failures, adverse events, and healthcare
costs.”
Mayo Clinic also receives access to a range of ABL’s virology products
for genotyping data analysis, either from Sanger or Next Generation
Sequencing. ABL’s products, ViroScore® Suite and DeepChek®,
are for research use only in the United States, and the upcoming data
processing module is an FDA registered class I medical device.
Financial
terms of the agreements have not been disclosed.
###
About ABL
Advanced
Biological Laboratories (ABL), S.A., is a medical data technology
company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL
took control of TherapyEdge, Inc. in 2004, and in 2013, the company
acquired the rights to all viral hepatitis B- and C-related assets from
EVIVAR MEDICAL. ABL has a comprehensive suite of health care management
products, including TherapyEdge®, ViroScore®,
SeqHepB, DeepChek®, VisibleChek®, HepatiC™
and OncoChek™, which are used for data and patient
management, monitoring, and personalized reporting applications. In
2012, some of ABL’s products received CE-marking for IVD use. ABL’s
products offer clinicians and laboratories optimal and efficient IT
solutions for sequencing, clinical genotyping, and drug-resistance
analysis, including powerful fully integrated databases and analysis
systems combining standard and high-throughput Next Generation
Sequencing data. Learn more at the company’s website: www.ablsa.com.
About the Mayo Clinic Department of Laboratory Medicine and Pathology
and Mayo Medical Laboratories
Mayo Medical Laboratories is the
reference laboratory of the Department of Laboratory Medicine and
Pathology at Mayo Clinic, a nonprofit worldwide leader in medical care,
research, and education for people from all walks of life. Mayo Medical
Laboratories is the third-largest provider of esoteric laboratory
services in the United States and serves more than 4,000 health care
organizations around the world. Complemented by collaborations with
diagnostic and biotechnology companies, the department maintains a
robust diagnostic test-development program, launching more than 150 new
tests each year. Ultimately, these new technologies and new testing are
available to the Mayo Clinic practice and other health care institutions
through Mayo Medical Laboratories. Revenue from this testing is used to
support medical education and research at Mayo Clinic.
